Despite this, across both cohorts, patients with CKD who tested positive were less likely to be prescribed an ACE-inhibitor or ARB at the time of their index SARS-CoV-2 test than those who tested negative (Cohort 1: 35.8% versus 41.5%; Cohort 2: 25.2% versus 36.7%) (table 1). This evidence concerns the gene ACE and chronic kidney disease.